On Tuesday, C4 Therapeutics Inc (NASDAQ: CCCC) was -2.24% drop from the session before settling in for the closing price of $2.23. A 52-week range for CCCC has been $1.09 – $4.03.
A company in the Healthcare sector has dropped its sales by -8.92% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 7.51%. With a float of $78.36 million, this company’s outstanding shares have now reached $96.91 million.
C4 Therapeutics Inc (CCCC) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward C4 Therapeutics Inc stocks. The insider ownership of C4 Therapeutics Inc is 19.14%, while institutional ownership is 57.47%. The most recent insider transaction that took place on Jan 16 ’26, was worth 22,200. In this transaction Chief Medical Officer of this company sold 10,000 shares at a rate of $2.22, taking the stock ownership to the 156,382 shares. Before that another transaction happened on Feb 18 ’25, when Company’s Chief Business Officer sold 669 for $3.15, making the entire transaction worth $2,107. This insider now owns 107,805 shares in total.
C4 Therapeutics Inc (CCCC) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.49 earnings per share (EPS) during the time that was less than consensus figure (set at -0.45) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.69% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
You can see what C4 Therapeutics Inc (CCCC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.67, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.22 in one year’s time.
